463 related articles for article (PubMed ID: 34167423)
21. Atezolizumab-bevacizumab plus Y-90 TARE for the treatment of hepatocellular carcinoma: preclinical rationale and ongoing clinical trials.
Di Federico A; Rizzo A; Carloni R; De Giglio A; Bruno R; Ricci D; Brandi G
Expert Opin Investig Drugs; 2022 Apr; 31(4):361-369. PubMed ID: 34798793
[TBL] [Abstract][Full Text] [Related]
22. Early experience of atezolizumab plus bevacizumab therapy in Japanese patients with unresectable hepatocellular carcinoma in real-world practice.
Hayakawa Y; Tsuchiya K; Kurosaki M; Yasui Y; Kaneko S; Tanaka Y; Ishido S; Inada K; Kirino S; Yamashita K; Nobusawa T; Matsumoto H; Kakegawa T; Higuchi M; Takaura K; Tanaka S; Maeyashiki C; Tamaki N; Nakanishi H; Itakura J; Takahashi Y; Asahina Y; Okamoto R; Izumi N
Invest New Drugs; 2022 Apr; 40(2):392-402. PubMed ID: 34586531
[TBL] [Abstract][Full Text] [Related]
23. Atezolizumab plus Bevacizumab versus Sorafenib in the Chinese Subpopulation with Unresectable Hepatocellular Carcinoma: Phase 3 Randomized, Open-Label IMbrave150 Study.
Qin S; Ren Z; Feng YH; Yau T; Wang B; Zhao H; Bai Y; Gu S; Li L; Hernandez S; Xu DZ; Mulla S; Wang Y; Shao H; Cheng AL
Liver Cancer; 2021 Jul; 10(4):296-308. PubMed ID: 34414118
[TBL] [Abstract][Full Text] [Related]
24. Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma progressing after molecular targeted therapy: A multicenter prospective observational study.
Sugimoto R; Satoh T; Ueda A; Senju T; Tanaka Y; Yamashita S; Koyanagi T; Kurashige T; Higuchi N; Nakamura T; Tanaka M; Azuma Y; Ohno A; Ooho A; Ooe M; Mutsuki T; Uchimura K; Kuniyoshi M; Tada S; Aratake Y; Yoshimoto T; Yamashita N; Harada S; Nakamuta M; Motomura K; Kohjima M;
Medicine (Baltimore); 2022 Oct; 101(40):e30871. PubMed ID: 36221372
[TBL] [Abstract][Full Text] [Related]
25. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: Results from a German real-world cohort.
Jost-Brinkmann F; Demir M; Wree A; Luedde T; Loosen SH; Müller T; Tacke F; Roderburg C; Mohr R
Aliment Pharmacol Ther; 2023 Jun; 57(11):1313-1325. PubMed ID: 36883351
[TBL] [Abstract][Full Text] [Related]
26. Real-World Data for Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma: How Does Adherence to the IMbrave150 Trial Inclusion Criteria Impact Prognosis?
Rimini M; Persano M; Tada T; Suda G; Shimose S; Kudo M; Cheon J; Finkelmeier F; Lim HY; Presa J; Masi G; Yoo C; Lonardi S; Piscaglia F; Kumada T; Sakamoto N; Iwamoto H; Aoki T; Chon HJ; Himmelsbach V; Pressiani T; Montes M; Vivaldi C; Soldà C; Hiraoka A; Sho T; Niizeki T; Nishida N; Steup C; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimura T; Hatanaka T; Kakizaki S; Shimada N; Kawata K; Tada F; Ohama H; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Kosaka H; Naganuma A; Koizumi Y; Nakamura S; Kaibori M; Iijima H; Hiasa Y; Burgio V; Rimassa L; Scartozzi M; Cascinu S; Casadei-Gardini A
Target Oncol; 2023 Mar; 18(2):221-233. PubMed ID: 36920648
[TBL] [Abstract][Full Text] [Related]
27. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study.
Ren Z; Xu J; Bai Y; Xu A; Cang S; Du C; Li Q; Lu Y; Chen Y; Guo Y; Chen Z; Liu B; Jia W; Wu J; Wang J; Shao G; Zhang B; Shan Y; Meng Z; Wu J; Gu S; Yang W; Liu C; Shi X; Gao Z; Yin T; Cui J; Huang M; Xing B; Mao Y; Teng G; Qin Y; Wang J; Xia F; Yin G; Yang Y; Chen M; Wang Y; Zhou H; Fan J;
Lancet Oncol; 2021 Jul; 22(7):977-990. PubMed ID: 34143971
[TBL] [Abstract][Full Text] [Related]
28. First-line immune checkpoint inhibitor-based combinations in unresectable hepatocellular carcinoma: current management and future challenges.
Rizzo A; Ricci AD; Gadaleta-Caldarola G; Brandi G
Expert Rev Gastroenterol Hepatol; 2021 Nov; 15(11):1245-1251. PubMed ID: 34431725
[TBL] [Abstract][Full Text] [Related]
29. [New approval: Atezolizumab and bevacizumab for first line of unresecable hepatocellular carcinoma].
Minot-This MS; Edeline J
Bull Cancer; 2021 Feb; 108(2):139-140. PubMed ID: 33546873
[No Abstract] [Full Text] [Related]
30. Organ-specific response with first-line atezolizumab-bevacizumab versus lenvatinib for patients with advanced hepatocellular carcinoma.
Kim HD; Park YG; Kim S; Kim KP; Park SR; Ryu MH; Ryoo BY; Yoo C
Hepatol Int; 2024 Jun; 18(3):973-983. PubMed ID: 38214792
[TBL] [Abstract][Full Text] [Related]
31. An update on atezolizumab for hepatocellular carcinoma.
Ielasi L; Sansone V; Forgione A; Granito A; Benevento F; Tovoli F
Drugs Today (Barc); 2021 Jun; 57(6):365-375. PubMed ID: 34151903
[TBL] [Abstract][Full Text] [Related]
32. Protocol of the RACB study: a multicenter, single-arm, prospective study to evaluate the efficacy of resection of initially unresectable hepatocellular carcinoma with atezolizumab combined with bevacizumab.
Okuno M; Ishii T; Ichida A; Soyama A; Takemura N; Hirono S; Eguchi S; Hasegawa K; Sasaki Y; Uemura K; Kokudo N; Hatano E
BMC Cancer; 2023 Aug; 23(1):780. PubMed ID: 37605169
[TBL] [Abstract][Full Text] [Related]
33. Atezolizumab in advanced hepatocellular carcinoma: good things come to those who wait.
Rizzo A; Ricci AD; Brandi G
Immunotherapy; 2021 Jun; 13(8):637-644. PubMed ID: 33820447
[TBL] [Abstract][Full Text] [Related]
34. Potential feasibility of atezolizumab-bevacizumab therapy in patients with hepatocellular carcinoma treated with tyrosine-kinase inhibitors.
Stefanini B; Bucci L; Santi V; Reggidori N; Rampoldi D; Lani L; Granito A; Sangiovanni A; Cabibbo G; Farinati F; Campani C; Foschi FG; Svegliati-Baroni G; Raimondo G; Gasbarrini A; Mega A; Biasini E; Sacco R; Morisco F; Caturelli E; Vidili G; Azzaroli F; Giannini EG; Rapaccini GL; Brunetto MR; Masotto A; Nardone G; Di Marco M; Magalotti D; Trevisani F;
Dig Liver Dis; 2022 Nov; 54(11):1563-1572. PubMed ID: 35906166
[TBL] [Abstract][Full Text] [Related]
35. Bevacizumab and atezolizumab as first-line therapy for advanced hepatocellular carcinoma: A Taiwanese subgroup analysis on efficacy and safety.
Shao YY; Feng YH; Yen CJ; Yang TS; Shen YC; Chao Y; Chen JS; Su CY; Chen WJ; Hsiang HL; Hsu CH
J Formos Med Assoc; 2022 Dec; 121(12):2430-2437. PubMed ID: 36153210
[TBL] [Abstract][Full Text] [Related]
36. Albumin-Bilirubin Grade Analyses of Atezolizumab plus Bevacizumab versus Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: A Post Hoc Analysis of the Phase III IMbrave150 Study.
Kudo M; Finn RS; Cheng AL; Zhu AX; Ducreux M; Galle PR; Sakamoto N; Kato N; Nakano M; Jia J; Vogel A
Liver Cancer; 2023 Oct; 12(5):479-493. PubMed ID: 37901766
[TBL] [Abstract][Full Text] [Related]
37. Comparative efficacy of novel combination strategies for unresectable hepatocellular carcinoma: A network metanalysis of phase III trials.
Fulgenzi CAM; D'Alessio A; Airoldi C; Scotti L; Demirtas CO; Gennari A; Cortellini A; Pinato DJ
Eur J Cancer; 2022 Oct; 174():57-67. PubMed ID: 35970037
[TBL] [Abstract][Full Text] [Related]
38. Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis.
Rimini M; Rimassa L; Ueshima K; Burgio V; Shigeo S; Tada T; Suda G; Yoo C; Cheon J; Pinato DJ; Lonardi S; Scartozzi M; Iavarone M; Di Costanzo GG; Marra F; Soldà C; Tamburini E; Piscaglia F; Masi G; Cabibbo G; Foschi FG; Silletta M; Pressiani T; Nishida N; Iwamoto H; Sakamoto N; Ryoo BY; Chon HJ; Claudia F; Niizeki T; Sho T; Kang B; D'Alessio A; Kumada T; Hiraoka A; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimur T; Hatanaka T; Kakizaki S; Shimada N; Kawata K; Tanaka T; Ohama H; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Naganuma A; Koizumi Y; Nakamura S; Joko K; Iijima H; Hiasa Y; Pedica F; De Cobelli F; Ratti F; Aldrighetti L; Kudo M; Cascinu S; Casadei-Gardini A
ESMO Open; 2022 Dec; 7(6):100591. PubMed ID: 36208496
[TBL] [Abstract][Full Text] [Related]
39. Angiogenesis and immune checkpoint dual blockade: Opportunities and challenges for hepatocellular carcinoma therapy.
Li SQ; Yang Y; Ye LS
World J Gastroenterol; 2022 Nov; 28(42):6034-6044. PubMed ID: 36405383
[TBL] [Abstract][Full Text] [Related]
40. AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer.
Antoniotti C; Borelli B; Rossini D; Pietrantonio F; Morano F; Salvatore L; Lonardi S; Marmorino F; Tamberi S; Corallo S; Tortora G; Bergamo F; Brunella DS; Boccaccino A; Grassi E; Racca P; Tamburini E; Aprile G; Moretto R; Boni L; Falcone A; Cremolini C
BMC Cancer; 2020 Jul; 20(1):683. PubMed ID: 32698790
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]